explore -WSS

explore

author：comprehensive 2025-09-05 13:47:10 - browse：7

insulin biosimilar — Last week, the FDA released a trio of guidelines clarifying the way they plan to evaluate devices that go through the 510(k) pathway. Jacquelyn Martin/AP

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

Most medical device companies do not have to test their products on people in order to secure clearance from the FDA — they simply have to show they’re “substantially equivalent” to devices already on the market, called “predicates.” This process is the 510(k) pathway, and accounts for the vast majority of new medical devices launched on the market each year. Devices cleared through this pathway include X-ray machines, muscle stimulators, and wheelchairs.

Last week, the FDA released a trio of guidelines clarifying the way it plans to evaluate devices that go through the 510(k) pathway. The agency is asking manufacturers to avoid predicate devices that were recalled due to a “design-related” issue or have “unmitigated” safety concerns. Manufacturers should submit flow charts explaining why they chose their predicate device. If they have to choose one with a recall history or safety issues, they should explain how the new device addresses those problems. The FDA may also ask the manufacturer for clinical data in this case.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： MultiPlan and major insurers sued for alleged medical price

WSS

After traumatic brain injury, life support decisions can use more time

Getting Alzheimer's drug Leqembi to patients can be a challenge

ALS advocates say criticism of new drugs misses bigger picture

Why rehabilitation engineers need to center patients in their research

AstraZeneca chief proposes a novel edit to the drug pricing bill

A new House health package & hospitals’ new site

hotspot

explore

focus

Moonlake's readout produced a cash windfall. Risks remain

Medicaid rebukes states for mistakenly disenrolling children

Supreme Court strikes down use of affirmative action

Why rehabilitation engineers need to center patients in their research

At least 13 dead in Texas as scorching temps continue

What drug price negotiations mean for Medicare Part D

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Wildfire smoke exposes gaps in outdoor worker protections

Why rehabilitation engineers need to center patients in their research

entertainment

Exact Sciences stock tumbles despite strong cancer detection sales

Cue Health's Covid

Weighted lottery helped low

Getting Alzheimer's drug Leqembi to patients can be a challenge

Health care needs a new profession: neuroimaging counseling

What drug price negotiations mean for Medicare Part D

focus

focus

Wikipedia

leisure time